The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Oral cancer: Current role of radiotherapy and chemotherapy
Open accessAbstract
The term oral cavity cancer (OSCC) constitutes cancers of the mucosal surfaces of the lips, floor of mouth, oral tongue, buccal mucosa, lower and upper gingiva, hard palate and retromolar trigone. Treatment approaches for OSCC include single management with surgery, radiotherapy [external beam radiotherapy (EBRT) and/or brachytherapy], as well as adjuvant systemic therapy (chemotherapy and/or target agents); various combinations of these modalities may also be used depending on the disease presentation and pathological findings. The selection of sole or combined modality is based on various considerations that include disease control probability, the anticipated functional and cosmetic outcomes, tumor resectability, patient general condition, and availability of resources and expertise. For resectable OSCC, the mainstay of treatment is surgery, though same practitioners may advocate for the use of radiotherapy alone in selected "early" disease presentations or combined with chemotherapy in more locally advanced stage disease. In general, the latter is more commonly reserved for cases where surgery may be problematic. Thus, primary radiotherapy ± chemotherapy is usually reserved for patients unable to tolerate or who are otherwise unsuited for surgery. On the other hand, brachytherapy may be considered as a sole modality for early small primary tumor. It also has a role as an adjuvant to surgery in the setting of inadequate pathologically assessed resection margins, as does postoperative external beam radiotherapy ± chemotherapy, which is usually reserved for those with unfavorable pathological features. Brachytherapy can also be especially useful in the re-irradiation setting for persistent or recurrent disease or for a second primary arising within a previous radiation field. Biological agents targeting the epithelial growth factor receptor (EGFR) have emerged as a potential modality in combination with radiotherapy or chemoradiotherapy and are currently under evaluation in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,115
Cooper, J. S., Pajak, T. F., Forastiere, A. A., Jacobs, J., Campbell, B. H., Saxman, S. B., Kish, J. A., Kim, H. E., Cmelak, A. J., Rotman, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032646 · Cited by 3,269
Bernier, J., Domenge, C., Ozsahin, M., Matuszewska, K., Lefèbvre, J.-L., Greiner, R. H., Giralt, J., Maingon, P., Rolland, F., Bolla, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032641 · Cited by 3,192
Pignon, J.-P., Maître, A. L., Maillard, E., & Bourhis, J. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2009.04.014 · Cited by 3,069
Bernier, J., Cooper, J. S., Pajak, T. F., van Glabbeke, M., Bourhis, J., Forastiere, A., Ozsahin, E. M., Jacobs, J. R., Jassem, J., Ang, K.-K., et al. (2005) · Head & Neck · doi:10.1002/hed.20279 · Cited by 1,772
Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis
Bourhis, J., Overgaard, J., Audry, H., Ang, K. K., Saunders, M., Bernier, J., Horiot, J.-C., Le Maître, A., Pajak, T. F., Poulsen, M. G., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69121-6 · Cited by 1,085
Self-citationDoes Delay in Starting Treatment Affect the Outcomes of Radiotherapy? A Systematic Review
Huang, J., Barbera, L., Brouwers, M., Browman, G., & Mackillop, W. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.171 · Cited by 586
Peters, L. J., Goepfert, H., Ang, K. K., Byers, R. M., Maor, M. H., Guillamondegui, O., Morrison, W. H., Weber, R. S., Garden, A. S., Frankenthaler, R. A., et al. (1993) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(93)90167-t · Cited by 538
The significance of “positive” margins in surgically resected epidermoid carcinomas
Looser, K. G., Shah, J. P., & Strong, E. W. (1978) · Head & Neck Surgery · doi:10.1002/hed.2890010203 · Cited by 376
Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment
Oliver, R., Clarkson, J., Conway, D. I., Glenny, A., Macluskey, M., Pavitt, S. H., Sloan, P., Panel, T. C. E., & Worthington, H. V. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006205.pub2 · Cited by 149
Cited by
Rivera, C. (2015) · PubMed · doi:10.5281/zenodo.192487 · Cited by 818
Overview of oral cavity squamous cell carcinoma: Risk factors, mechanisms, and diagnostics
Chamoli, A., Gosavi, A. S., Shirwadkar, U. P., Wangdale, K. V., Behera, S. K., Kurrey, N. K., Kalia, K., & Mandoli, A. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2021.105451 · Cited by 589
Tongue cancer tailored photosensitizers for NIR-II fluorescence imaging guided precise treatment
Yin, B., Qin, Q., Li, Z., Wang, Y., Liu, X., Liu, Y., Huan, S., Zhang, X., & Song, G. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101550 · Cited by 65
Qin, J., Zhou, C., Zhu, M., Shi, S., Zhang, L., Zhao, Y., Li, C., Wang, Y., & Wang, Y. (2020) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2020.101907 · Cited by 17
Yin, X., Li, Z., Zhang, Y., Zeng, X., Wang, Q., & Liang, Z. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1174014 · Cited by 15
“Some postoperative patients have to accept postoperative radiotherapy and chemotherapy due to an insufficient pathological evaluation margin and a highly malignant pathological classification (Huang and O’Sullivan, 2013).”
Background
Metadata
- Authors
- Huang, S., & O Sullivan, B.
- Venue
- Medicina Oral Patología Oral y Cirugia Bucal
- Publisher
- Medicina Oral, S.L.
- Published
- 2013
- Volume
- 18
- Issue
- 2
- Pages
- e233-e240
- ISSN
- 1698-4447 (ISSN-L)
- 1698-6946
- OpenAlex
- W2123308199
- Cited by
- 349
- References
- 17
- FWCI
- 11.67
- Type
- journal article
- Language
- es
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oral cancer: Current role of radiotherapy and chemotherapy. https://app.cochat.ai/papers/10.4317/medoral.18772
- The paper
- Huang, S., & O Sullivan, B. (2013). Oral cancer: Current role of radiotherapy and chemotherapy. Medicina Oral Patología Oral y Cirugia Bucal. https://doi.org/10.4317/medoral.18772
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.